Profile data is unavailable for this security.
About the company
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
- Revenue in SEK (TTM)93.90m
- Net income in SEK-296.40m
- Incorporated2006
- Employees32.00
- LocationEgetis Therapeutics AB (publ)Klara Norra Kyrkogata 26STOCKHOLM 111 22SwedenSWE
- Phone+46 86797210
- Fax+46 86635725
- Websitehttps://www.egetis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcticzymes Technologies ASA | 112.63m | 14.19m | 859.64m | 68.00 | 60.49 | 2.78 | 42.69 | 7.63 | 0.2867 | 0.2867 | 2.27 | 6.24 | 0.3485 | 0.5349 | 6.83 | 1,706,250.00 | 4.39 | 15.58 | 4.63 | 17.22 | 94.39 | 96.69 | 12.60 | 33.23 | 17.25 | -- | 0.0298 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Alligator Bioscience AB | 45.71m | -234.30m | 1.00bn | 51.00 | -- | -- | -- | 21.93 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Egetis Therapeutics AB (publ) | 93.90m | -296.40m | 1.34bn | 32.00 | -- | 3.34 | -- | 14.30 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -214.76m | 1.35bn | 26.00 | -- | 2.48 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 186.00k | -139.62m | 1.40bn | 25.00 | -- | 7.39 | -- | 7,537.94 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Nightingale Health Oyj | 41.50m | -205.09m | 1.51bn | 81.00 | -- | 2.22 | -- | 36.49 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Vicore Pharma Holding AB | 104.24m | -200.07m | 1.57bn | 28.00 | -- | 1.85 | -- | 15.05 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Nanoform Finland Oyj | 26.06m | -246.06m | 1.59bn | 174.00 | -- | 1.98 | -- | 61.06 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Nykode Therapeutics ASA | 62.43m | -385.08m | 1.74bn | 179.00 | -- | 1.12 | -- | 27.82 | -1.27 | -1.27 | 0.2011 | 4.87 | 0.0333 | -- | 1.59 | 371,776.30 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.75bn | 5.00 | -- | 6.92 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
Data as of Sep 20 2024. Currency figures normalised to Egetis Therapeutics AB (publ)'s reporting currency: Swedish Krona SEK
15.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 21.40m | 7.32% |
| Handelsbanken Fonder ABas of 31 Dec 2023 | 11.83m | 4.04% |
| Unionen (Investment Management)as of 31 Dec 2023 | 6.95m | 2.37% |
| SEB Investment Management ABas of 30 Aug 2024 | 1.52m | 0.52% |
| Swedbank Robur Fonder ABas of 30 Aug 2024 | 1.00m | 0.34% |
| FCG Fonder ABas of 30 Aug 2024 | 992.02k | 0.34% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 500.00k | 0.17% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 426.93k | 0.15% |
| Skandia Investment Management ABas of 31 Jul 2024 | 174.51k | 0.06% |
| Storebrand Asset Management ASas of 31 Aug 2024 | 73.90k | 0.03% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
